[
  {
    "question_id": "cs03_q01_longitudinal",
    "scope_id": "clinical_signal_03",
    "checkpoint_after": 12,
    "question_type": "longitudinal",
    "prompt": "Based on the trial data so far, are there any emerging safety signals in the lab panels?",
    "ground_truth": {
      "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
      "required_evidence_refs": [
        "clinical_signal_03_ep_010",
        "clinical_signal_03_ep_013"
      ],
      "key_facts": [
        "progressive transaminase creep in co-medicated cohort trending toward action threshold"
      ]
    }
  },
  {
    "question_id": "cs03_q02_null",
    "scope_id": "clinical_signal_03",
    "checkpoint_after": 12,
    "question_type": "null_hypothesis",
    "prompt": "What was the enrollment count at Site 03 in the Week 6 summary?",
    "ground_truth": {
      "canonical_answer": "The enrollment figure as documented in the Week 6 site summary.",
      "required_evidence_refs": [
        "clinical_signal_03_ep_006"
      ],
      "key_facts": []
    }
  },
  {
    "question_id": "cs03_q03_longitudinal",
    "scope_id": "clinical_signal_03",
    "checkpoint_after": 25,
    "question_type": "longitudinal",
    "prompt": "What is driving the hepatic adverse events in this trial?",
    "ground_truth": {
      "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
      "required_evidence_refs": [
        "clinical_signal_03_ep_010",
        "clinical_signal_03_ep_018",
        "clinical_signal_03_ep_023",
        "clinical_signal_03_ep_015"
      ],
      "key_facts": [
        "progressive transaminase creep in co-medicated cohort trending toward action threshold",
        "hepatic signal present across multiple sites not just Site 07",
        "drug-drug interaction with statin via CYP3A4 inhibition",
        "Site 07 lab equipment issue is not the cause of ALT elevations"
      ]
    }
  },
  {
    "question_id": "cs03_q04_action",
    "scope_id": "clinical_signal_03",
    "checkpoint_after": 30,
    "question_type": "action_recommendation",
    "prompt": "What protocol amendments should the DSMB recommend?",
    "ground_truth": {
      "canonical_answer": "Exclude concomitant statin use from the trial. Add CYP3A4 interaction screening. Implement more frequent hepatic panel monitoring for enrolled subjects. Consider dose adjustment studies for the LNS-4821/statin interaction.",
      "required_evidence_refs": [
        "clinical_signal_03_ep_019",
        "clinical_signal_03_ep_023",
        "clinical_signal_03_ep_026"
      ],
      "key_facts": [
        "drug-drug interaction with statin via CYP3A4 inhibition",
        "progressive transaminase creep in co-medicated cohort trending toward action threshold"
      ]
    }
  }
]